Bio is where the partners' track record began — botulinum toxins, peptides, stem cells, and the funds that backed them. SOLOMON PARTNERS invests in, raises capital for, and independently evaluates life-science companies with the same data-first discipline it applies to silicon and flight systems.
The partners have built and financed bio ventures since 2015 — Protox in botulinum toxins, Premier Bio and Gwell Bio in novel-substance research, Pepgen in peptides, Hucode in cord-blood stem cells — and formed dedicated bio investment associations along the way. That operating history is the foundation of our coverage.
Life science rewards the same discipline as deep tech: claims are testable, data has provenance, and regulatory pathways decide commercial reality. We treat clinical and preclinical data the way we treat flight-test data — as the source of truth beneath the valuation.
Preclinical and clinical data integrity, GMP manufacturing readiness, regulatory pathway credibility (MFDS, FDA, EMA), intellectual-property position and freedom to operate, platform-versus-single-asset economics, licensing and technology-transfer terms, and the translational gap between publication and product.
Through Principal Investments we take positions across the capital structure — venture and growth equity, special situations, and co-investment alongside institutional partners — always underwritten by our own technical work rather than borrowed conviction.
Through our Technology Advisory practice we deliver independent assessments, technical due diligence, and written expert opinions in this sector for investors, boards, lenders, corporates, and government programs. Through Capital Formation we prepare and run fundraising processes for companies whose technology withstands our own scrutiny.
We invest in it, raise capital for it, and evaluate it. Tell us where you sit, and we will bring the relevant practice to the table.